Sintesis Tiga Peptida Bergugus Pelindung sebagai Prekursor Komponen Vaksin Influenza Universal

Toto Subroto, Ari Hardianto, Abdul Alim Kahari, Tika Pradnjaparamita


Current highly effective conventional vaccine to halt the spread of bird flu has not been invented yet because of susceptiblemutation of influenza virus. In spite of undergoing mutation which causes the amino acid sequence change, influenzaviruses maintain conservation at ectodomain of M2 protein, especially M2e(2-16) (SLLTEVETPIRNEW). The use ofconserved epitope M2e(2-16) in epitope-based vaccine potentially produces universal influenza vaccine. In designingepitope-based vaccine, the M2e(2-16) needs to be coupled with T helper epitope, P25, which is subsequently mentioned asM2e(2-16)-K-P25 (SLLTEVETPIRNEWGKKKL IPNASLIENCTKAEL). The M2e(2-16)-K-P25 was synthesized usingconvergent solid phase peptide synthesis strategy because of the size of the sequence. In this strategy, four peptideprecursors of M2e(2-16)-K-P25; SLLTEVETP (F1), IRNEWGK (F2), KLIPNASLI (F3), and ENCTKAEL (F4); were synthesizedin advance. After the precursors ready, coupling reaction was performed to obtain M2e(2-16)-K-P25. In the previousresearch, F3 has been obtained in high purity through Fmoc/tBu solid phase peptide synthesis method. In this conductedresearch, the three remaining precursors; F1, F2, and F4; were synthesized by the same method. Each peptide was analysedby thin layer chromatography, HPLC, and mass spectroscopy methods. F1, F2 and F4 were successfully synthesized andeach of them was detected at 1490.0, 1874.8 and 1881.9 amu, respectively. However, F1 was not possible to purify becauseof its insolubility in various solvents.


bird flu, epitope, precursor, solid phase peptide synthesis, universal influenza vaccine

Full Text:



Albericio, F. 2004. Developments in peptide and amide synthesis. Curr Opin Chem Biol 8(3): 211–21.

Alphs, H.H., Gambhira, R., Karanam, B., Roberts, J.N., Jagu, S., Schiller, J.T., Zeng, W., Jackson, D.C & Roden, R.B.S. 2008. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross- neutralizing epitope of L2. Proc. Natl. Acad. Sci. U. S. A. 105, 5850–5.

Barlos, K., Gatos, D. 1999. tButyl-Based Convergent. Biopolymers 51: 266–278.

Betakova, T. 2007. M2 Protein – A Proton Channel of Influenza A Virus. Curr Pharm Des 13: 3231–3235


Carrat, F & Flahault, A. 2007. Influenza Vaccine: The Challenge of Antigenic Drift. Vaccine 25: 6852–62.

Chan, W.C & White, P.D. 2000. Fmoc Solid Phase Peptide Synthesis: A Practical Approach, Molecular Biology. New York: Oxford University Press.

Fiers, W., De Filette, M., Birkett, A., Neirynck, S., Min & Jou, W. 2004. A “Universal” Human Influenza A Vaccine. Virus Res 103: 173–6.

Flower, D.R., 2008. Bioinformatics for Vaccinology, Vaccine. John Wiley & Sons, Ltd, Chichester, UK.

Gairí, M., Lloyd-Williams, P., Albericio, F & Giralt, E., 1995. Convergent solid-phase peptide synthesis 12. * Chromatographic techniques for the purification of protected peptide segments. Int. J. Pept. Protein Res 46: 119–133.

Ghosh, S., Walker, J & Jackson, D.C., 2001. Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus. Immunology 104: 58–66.

Hardianto, A., Subroto, T & Supratman, U., 2011. Sintesis Peptida P251-9 Bergugus Pelindung dengan Metode Sintesis Peptida Fase Padat Fmoc/tBu Menggunakan Aditif Oksima. Sains dan Terap. Kim 5: 131–139.

Jackson, D.C., Chua, B & Zeng, W. 2006. Totally Synthetic Peptide-based Vaccines that Target Dendritic Cells and Induce Potent Antibody or CTL Responses. Int. Congr. Ser 1289: 311–315.

Jackson, D.C., Lau, Y.F., Le, T., Suhrbier, A., Deliyannis, G., Cheers, C., Smith, C., Zeng, W & Brown, L.E., 2004. ATotally Synthetic Vaccine of Generic Structure that Targets Toll-like Receptor 2 on Dendritic Cells and Promotes Antibody or Cytotoxic T Cell Responses. Proc. Natl. Acad. Sci. U. S. A. 101, 15440– 5. doi:10.1073/pnas.0406740101.

Narita, M., Ishikawa, K., Chen, J.Y & Kim, Y. 1984. Prediction and improvement of protected peptide solubility in organic solvents. Int. J. Pept. Protein Res 24: 580–587.

Pejoski, D., Zeng, W., Rockman, S., Brown, L.E & Jackson, D.C. 2010. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol. Cell Biol 88: 605–11.

Sette, A & Fikes, J. 2003. Epitope-based Vaccines: An Update on Epitope Identification, Vaccine Design and Delivery. Curr. Opin. Immunol 15: 461–470.

Subirós-Funosas, R., Prohens, R., Barbas, R., El-Faham, A &Albericio, F., 2009. Oxyma: an efficient additive for peptide synthesis to replace the benzotriazole- based HOBt and HOAt with a lower risk of explosion. Chemistry 15: 9394–403.

Toth, I., Simerska, P & Fujita, Y. 2008. Recent Advances in Design and Synthesis of Self-Adjuvanting Lipopeptide Vaccines. Int. J. Pept. Res. Ther 14: 333– 340.

Wang, R., Song, A., Levin, J., Dennis, D., Zhang, N.J., Yoshida, H.H., Koriazova, L., Madura, L., Shapiro, L., Matsumoto, A., Mikayama, T., Kubo, R.T., Sarawar, S., Cheroutre, H & Kato, S., 2008. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 80: 168–77.



  • There are currently no refbacks.

Copyright (c) 2015 Toto Subroto, Ari Hardianto, Abdul Alim Kahari, Tika Pradnjaparamita

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.